Eshuis Emma J, Bemelman Willem A, Stokkers Pieter C F
Department of Surgery, Academic Medical Center, 1105 AZ, Amsterdam, The Netherlands.
Expert Rev Gastroenterol Hepatol. 2009 Jun;3(3):219-29. doi: 10.1586/egh.09.19.
Infliximab (IFX), an anti-TNF biologic agent, has been demonstrated to offer benefits for the treatment of autoimmune disorders, such as rheumatoid arthritis and Crohn's disease. Several trials have also investigated the efficacy of IFX for the treatment of ulcerative colitis (UC). IFX was found to be well tolerated. In most trials, IFX treatment was more effective than placebo for patients with moderate, moderate-to-severe or severe UC. However, its place in the treatment algorithms for UC remains to be defined and, to this end, clinical trials comparing IFX treatment to conventional therapies are needed.
英夫利昔单抗（IFX）是一种抗肿瘤坏死因子生物制剂，已被证明对治疗自身免疫性疾病有益，如类风湿性关节炎和克罗恩病。多项试验也研究了英夫利昔单抗治疗溃疡性结肠炎（UC）的疗效。发现英夫利昔单抗耐受性良好。在大多数试验中，对于中度、中度至重度或重度溃疡性结肠炎患者，英夫利昔单抗治疗比安慰剂更有效。然而，其在溃疡性结肠炎治疗方案中的地位仍有待确定，为此，需要进行将英夫利昔单抗治疗与传统疗法进行比较的临床试验。
